BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kudo M, Kitano M, Sakurai T, Nishida N. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan. Dig Dis 2015;33:765-70. [PMID: 26488173 DOI: 10.1159/000439101] [Cited by in Crossref: 135] [Cited by in F6Publishing: 175] [Article Influence: 16.9] [Reference Citation Analysis]
Number Citing Articles
1 Mima K, Hayashi H, Yumoto S, Matsumoto T, Tsukamoto M, Miyata T, Nakagawa S, Nitta H, Baba H. Disability in perioperative activities of daily living is associated with worse survival outcomes following hepatic resection in patients with intrahepatic cholangiocarcinoma. Hepatol Res 2023;53:135-44. [PMID: 36305859 DOI: 10.1111/hepr.13849] [Reference Citation Analysis]
2 Sideris GA, Tsaramanidis S, Vyllioti AT, Njuguna N. The Role of Branched-Chain Amino Acid Supplementation in Combination with Locoregional Treatments for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis. Cancers 2023;15:926. [DOI: 10.3390/cancers15030926] [Reference Citation Analysis]
3 Dai YS, Hu HJ, Lv TR, Hu YF, Zou RQ, Li FY. The influence of resection margin width in patients with intrahepatic cholangiocarcinoma: a meta-analysis. World J Surg Oncol 2023;21:16. [PMID: 36658564 DOI: 10.1186/s12957-023-02901-5] [Reference Citation Analysis]
4 Chuang YH, Cheng YF, Tsang LL, Ou HY, Hsu HW, Lim WX, Huang PH, Weng CC, Yu CY. Efficacy and Safety of Combined Ethanol-Lipiodol Mixture and Drug-Eluting Bead TACE for Large HCC. J Hepatocell Carcinoma 2023;10:81-90. [PMID: 36685112 DOI: 10.2147/JHC.S398434] [Reference Citation Analysis]
5 Ishikawa T, Egusa M, Fujioka T, Nishiyama N, Kawamoto D, Sasaki R, Nishimura T, Tanabe N, Oono T, Saeki I, Takami T. A combination of liver stiffness and international normalized ratio is an ideal prognostic predictor of portosystemic shunt occlusion in patients with portal hypertension. J Gastroenterol 2022. [PMID: 36583759 DOI: 10.1007/s00535-022-01947-8] [Reference Citation Analysis]
6 Cassese G, Han HS, Cho JY, Lee HW, Lee B, Troisi RI. Selecting the Best Approach for the Treatment of Multiple Non-Metastatic Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 36497478 DOI: 10.3390/cancers14235997] [Reference Citation Analysis]
7 Zhang W, Huang Z, Che X. Emergency versus delayed hepatectomy following transarterial embolization in spontaneously ruptured hepatocellular carcinoma survivors: a systematic review and meta-analysis. World J Surg Onc 2022;20:365. [DOI: 10.1186/s12957-022-02832-7] [Reference Citation Analysis]
8 Ohama H, Hiraoka A, Tada F, Kato K, Fukunishi Y, Yanagihara E, Kato M, Saneto H, Izumoto H, Ueki H, Yoshino T, Kitahata S, Kawamura T, Kuroda T, Suga Y, Miyata H, Hirooka M, Abe M, Matsuura B, Ninomiya T, Hiasa Y. Comparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative Treatment. Cancers (Basel) 2022;14. [PMID: 36428616 DOI: 10.3390/cancers14225524] [Reference Citation Analysis]
9 Heo CK, Lim WH, Park I, Choi YS, Lim KJ, Cho EW. Serum BRD2 autoantibody in hepatocellular carcinoma and its detection using mimotope peptide‑conjugated BSA. Int J Oncol 2022;61:158. [PMID: 36321789 DOI: 10.3892/ijo.2022.5448] [Reference Citation Analysis]
10 Watanabe Y, Aikawa M, Kato T, Takase K, Watanabe Y, Okada K, Okamoto K, Koyama I. Influence of Child-Pugh B7 and B8/9 cirrhosis on laparoscopic liver resection for hepatocellular carcinoma: a retrospective cohort study. Surg Endosc 2022. [PMID: 36203111 DOI: 10.1007/s00464-022-09677-x] [Reference Citation Analysis]
11 Gwon JG, Ko SY, Kim H. Is the platelet function test effective in predicting blood loss in patients undergoing hepatic resection? Ann Surg Treat Res 2022;103:227-34. [PMID: 36304195 DOI: 10.4174/astr.2022.103.4.227] [Reference Citation Analysis]
12 Bae SK, Arita J, Akamatsu N, Maki H, Nishioka Y, Kawahara T, Miyata A, Kokudo T, Nagata R, Mihara Y, Ichida A, Inagaki Y, Kawaguchi Y, Ishizawa T, Kaneko J, Tamura S, Tanaka Y, Moriya K, Hasegawa K. The impact of the covalently closed circular DNA level on recurrence of hepatocellular carcinoma after initial hepatectomy: an analysis of patients with resolved hepatitis B virus infection. HPB (Oxford) 2022;24:1780-8. [PMID: 35863998 DOI: 10.1016/j.hpb.2022.06.013] [Reference Citation Analysis]
13 Yoon JH, Choi SK, Cho SB, Kim HJ, Ko YS, Jun CH. Early extrahepatic recurrence as a pivotal factor for survival after hepatocellular carcinoma resection: A 15-year observational study. World J Gastroenterol 2022; 28(36): 5351-5363 [DOI: 10.3748/wjg.v28.i36.5351] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yang WL, Zhu F, Chen WX. Texture analysis of contrast-enhanced magnetic resonance imaging predicts microvascular invasion in hepatocellular carcinoma. Eur J Radiol 2022;156:110528. [PMID: 36162156 DOI: 10.1016/j.ejrad.2022.110528] [Reference Citation Analysis]
15 Tomonari T, Tani J, Sato Y, Tanaka H, Tanaka T, Taniguchi T, Morishita A, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Masaki T, Takayama T. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve. Cancer Med 2022. [PMID: 35964253 DOI: 10.1002/cam4.5145] [Reference Citation Analysis]
16 Bhangui P. Liver transplantation and portal vein tumour thrombus: futile enterprise? Curr Opin Organ Transplant 2022;27:312-9. [PMID: 36354257 DOI: 10.1097/MOT.0000000000000997] [Reference Citation Analysis]
17 Kariyama K, Hiraoka A, Kumada T, Yasuda S, Toyoda H, Tsuji K, Hatanaka T, Kakizaki S, Naganuma A, Tada T, Takaguchi K, Itobayashi E, Ishikawa T, Shimada N, Tsutsui A, Nagano T, Imai M, Nakamura S, Wakuta A, Miyake N, Shiota S, Nouso K. Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade). J Gastroenterol 2022;57:581-6. [PMID: 35763116 DOI: 10.1007/s00535-022-01883-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Mima K, Imai K, Kaida T, Matsumoto T, Nakagawa S, Sawayama H, Hayashi H, Yamashita YI, Baba H. Impairment of perioperative activities of daily living is associated with poor prognosis following hepatectomy for hepatocellular carcinoma. J Surg Oncol 2022. [PMID: 35796726 DOI: 10.1002/jso.26996] [Reference Citation Analysis]
19 Fukumoto T, Minami T, Moriyama M, Yamada T, Wake T, Kinoshita MN, Fujiwara N, Nakagomi R, Nakatsuka T, Sato M, Enooku K, Nakagawa H, Fujishiro M, Shiina S, Koike K, Tateishi R. Improved prognosis of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antivirals. Hepatol Commun 2022. [PMID: 35641233 DOI: 10.1002/hep4.2010] [Reference Citation Analysis]
20 Shigematsu Y, Amori G, Kanda H, Takahashi Y, Takazawa Y, Takeuchi K, Inamura K. Decreased ARG1 expression as an adverse prognostic phenotype in non-alcoholic non-virus-related hepatocellular carcinoma. Virchows Arch 2022. [PMID: 35459975 DOI: 10.1007/s00428-022-03318-3] [Reference Citation Analysis]
21 Xia F, Ndhlovu E, Zhang M, Chen X, Zhang B, Zhu P. Ruptured Hepatocellular Carcinoma: Current Status of Research. Front Oncol 2022;12:848903. [DOI: 10.3389/fonc.2022.848903] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
22 Xie Q, Liu H, Guo Z, Wu Y, He G, Cai L, Pan M, Fu S. Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy. Front Mol Biosci 2022;8:810251. [DOI: 10.3389/fmolb.2021.810251] [Reference Citation Analysis]
23 Guo XY, Xia YL, Li ZY, Li R, Fan Y, Yao WM, Liu F. Fas -670 A/G polymorphism predicts prognosis of hepatocellular carcinoma after curative resection in Chinese Han population. Hepatobiliary Pancreat Dis Int 2022;21:33-40. [PMID: 34366198 DOI: 10.1016/j.hbpd.2021.07.001] [Reference Citation Analysis]
24 Tanaka K, Tsuji K, Matsui T, Kang JH, Sakurai Y, Kodama Y, Minami R, Watanabe K, Katanuma A. Potential of PALBI-T score as a prognostic model for hepatocellular carcinoma in alcoholic liver disease. JGH Open 2022;6:36-43. [PMID: 35071786 DOI: 10.1002/jgh3.12705] [Reference Citation Analysis]
25 Cheng S, Yu X, Liu S, Jin Z, Xue H, Wang Z, Xie P. Development of a Prognostic Nomogram in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Trans-Arterial Chemoembolization with Drug-Eluting Beads. Cancer Manag Res 2021;13:9367-77. [PMID: 34992462 DOI: 10.2147/CMAR.S341672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zhang ZY, Zhang EL, Zhang BX, Zhang W. Surgery for hepatocellular carcinoma with tumor thrombosis in inferior vena cava: A case report. World J Clin Cases 2021; 9(36): 11495-11503 [DOI: 10.12998/wjcc.v9.i36.11495] [Reference Citation Analysis]
27 Zheng L, Gu X, Zheng G, Li X, He M, Liu L, Zhou X. Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection. PeerJ 2021;9:e12554. [PMID: 34900444 DOI: 10.7717/peerj.12554] [Reference Citation Analysis]
28 Serenari M, Cappelli A, Cucchetti A, Mosconi C, Strigari L, Monari F, Ravaioli M, Rizzini EL, Fanti S, Golfieri R, Cescon M. Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transpl 2021;27:1758-66. [PMID: 34355489 DOI: 10.1002/lt.26257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
29 Tomonari T, Sato Y, Tanaka H, Mitsuhashi T, Hirao A, Tanaka T, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Takayama T. Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. JGH Open 2021;5:1275-83. [PMID: 34816013 DOI: 10.1002/jgh3.12663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Piskin FC, Balli HT, Erdoğan KE, Sozutok S, Aikimbaev K. Whole tumor volumetric ADC analysis: relationships with histopathological differentiation of hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:5180-9. [PMID: 34415410 DOI: 10.1007/s00261-021-03240-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
32 Ogawa S, Kubo H, Murayama Y, Kubota T, Yubakami M, Matsumoto T, Yamamoto Y, Morimura R, Ikoma H, Okamoto K, Kamiya M, Urano Y, Otsuji E. Rapid fluorescence imaging of human hepatocellular carcinoma using the β-galactosidase-activatable fluorescence probe SPiDER-βGal. Sci Rep 2021;11:17946. [PMID: 34504174 DOI: 10.1038/s41598-021-97073-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Hara Y, Yamamura K, Matsumura K, Oda E, Akahoshi S, Yuki H, Tomiguchi J, Motohara T, Miyamoto H, Komohara Y, Beppu T. Laparoscopic Surgery for a Patient With Multiple Liver Metastases of Unknown Origin Concomitant With Gallbladder Tumor. In Vivo 2021;35:2963-8. [PMID: 34410995 DOI: 10.21873/invivo.12590] [Reference Citation Analysis]
34 Hiraoka A, Kumada T, Tada T, Tani J, Kariyama K, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Aoki T, Tanaka T, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Arai T, Okubo T, Imai M, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Sci Rep 2021;11:16663. [PMID: 34404856 DOI: 10.1038/s41598-021-96089-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
35 Shirai D, Shinkawa H, Takemura S, Tanaka S, Amano R, Kimura K, Kinoshita M, Kawada N, Kubo S. Impact of alcohol abstinence on survival after hepatic resection for hepatocellular carcinoma in patients with alcohol-related liver disease. Ann Med Surg (Lond) 2021;68:102644. [PMID: 34386231 DOI: 10.1016/j.amsu.2021.102644] [Reference Citation Analysis]
36 Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, Zhang X, Wang XD, Cao G, Chen H, Liu P, Zhu LZ, Xu HF, Yang RJ. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. Biomed Res Int 2021;2021:6670367. [PMID: 34337041 DOI: 10.1155/2021/6670367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
37 Tada T, Kumada T, Hiraoka A, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. Sci Rep 2021;11:14474. [PMID: 34262065 DOI: 10.1038/s41598-021-93794-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
38 Hiraoka A, Kumada T, Kariyama K, Tada T, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. J Gastroenterol Hepatol 2021;36:1812-9. [PMID: 33171524 DOI: 10.1111/jgh.15336] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
39 Oura K, Takuma K, Nakahara M, Tadokoro T, Fujita K, Mimura S, Tani J, Morishita A, Kobara H, Masaki T. Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature. Mol Clin Oncol 2021;15:154. [PMID: 34178325 DOI: 10.3892/mco.2021.2316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Yoon JH, Lee WJ, Kim SM, Kim KT, Cho SB, Kim HJ, Ko YS, Kook HY, Jun CH, Choi SK, Kim BS, Cho SY, You HS, Lee Y, Son S. Simple parameters predicting extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Sci Rep 2021;11:12984. [PMID: 34155324 DOI: 10.1038/s41598-021-92503-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Shimamura Y, Abe K, Maeda T, Matsui T, Ishiguro A, Takizawa H. Association Between Renal Adverse Effects and Mortality in Patients With Hepatocellular Carcinoma Treated With Lenvatinib. In Vivo 2021;35:1647-53. [PMID: 33910848 DOI: 10.21873/invivo.12423] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Chung SW, Park MK, Cho YY, Park Y, Lee CH, Oh H, Jang H, Kim MA, Kim SW, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim HC, Kim YJ, Chung JW, Yoon JH, Lee JH. Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. J Hepatocell Carcinoma 2021;8:587-98. [PMID: 34164351 DOI: 10.2147/JHC.S294440] [Reference Citation Analysis]
43 Yamamoto M, Kobayashi T, Hashimoto M, Kuroda S, Kawaoka T, Aikata H, Chayama K, Ohdan H. Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification. BMC Cancer 2021;21:668. [PMID: 34090354 DOI: 10.1186/s12885-021-08421-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Ma KW, Chan ACY, Chok KSH, She WH, Cheung TT, Dai WC, Fung JYY, Lo CM. Liver transplantation: would it be the best and last chance of cure for hepatocellular carcinoma with major venous invasion? Hepatobiliary Surg Nutr 2021;10:308-14. [PMID: 34159158 DOI: 10.21037/hbsn.2020.03.09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 She WH, Chan ACY, Ma KW, Dai WC, Chok KSH, Cheung TT, Lo CM. Critical appraisal of TNM versus HKU staging system for postoperative prognostic evaluation of hepatocellular carcinoma. Ann Transl Med 2021;9:919. [PMID: 34350234 DOI: 10.21037/atm-20-7611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
47 Kawabe N, Hashimoto S, Nakano T, Nakaoka K, Fukui A, Yoshioka K. Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. JGH Open 2021;5:705-11. [PMID: 34124389 DOI: 10.1002/jgh3.12573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Wang J, Wang J, Wang J, Qian Z, Xu W, Hang X. Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report. J Int Med Res 2021;49:300060521994406. [PMID: 33596694 DOI: 10.1177/0300060521994406] [Reference Citation Analysis]
49 Tani J, Senoh T, Moriya A, Ogawa C, Deguchi A, Sakamoto T, Takuma K, Nakahara M, Oura K, Tadokoro T, Mimura S, Fujita K, Yoneyama H, Kobara H, Morishita A, Himoto T, Tsutsui A, Nagano T, Takaguchi K, Masaki T. Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers (Basel) 2021;13:2257. [PMID: 34066708 DOI: 10.3390/cancers13092257] [Reference Citation Analysis]
50 Hiraoka A, Kato M, Marui K, Murakami T, Onishi K, Adachi T, Matsuoka J, Ueki H, Yoshino T, Tsuruta M, Aibiki T, Okudaira T, Kuroda T, Iwasaki R, Suga Y, Miyata H, Ninomiya T, Hirooka M, Abe M, Matsuura B, Michitaka K, Hiasa Y. Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker. Cancer Med 2021;10:3584-92. [PMID: 33960691 DOI: 10.1002/cam4.3908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
51 Kwon JH, Song GW, Hwang S, Kim KH, Ahn CS, Moon DB, Ha TY, Jung DH, Park GC, Yoon YI, Shim JH, Kim KW, Lee SG. Surgical Outcomes of Spontaneously Ruptured Hepatocellular Carcinoma. J Gastrointest Surg 2021;25:941-53. [PMID: 32246392 DOI: 10.1007/s11605-020-04555-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
52 Tomonari T, Sato Y, Tani J, Hirose A, Ogawa C, Morishita A, Tanaka H, Tanaka T, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Uchida K, Masaki T, Takayama T. Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis. Hepatol Res 2021;51:472-81. [PMID: 33238074 DOI: 10.1111/hepr.13597] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
53 Qiu Z, Wang G, Yang G, Wang G, Jiang W, Chen Z, Zhu W, Guo H, Zhang F, Gao F. Transcriptome sequencing-based personalized analysis of hepatocellular carcinoma patients with portal vein tumor thrombus. J Gastrointest Oncol 2021;12:795-805. [PMID: 34012667 DOI: 10.21037/jgo-21-162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
54 Hiraoka A, Kumada T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M. What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure? Liver Cancer 2021;10:115-25. [PMID: 33977088 DOI: 10.1159/000513355] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
55 Zhou M, Shan D, Zhang C, Nie J, Wang G, Zhang Y, Zhou Y, Zheng T. Value of gadoxetic acid-enhanced MRI for microvascular invasion of small hepatocellular carcinoma: a retrospective study. BMC Med Imaging 2021;21:40. [PMID: 33673821 DOI: 10.1186/s12880-021-00572-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Zhou C, Zu QQ, Liu XL, Wang B, Zhou CG, Shi HB, Liu S. Treatment strategies and prognosis for initially unresectable ruptured hepatocellular carcinoma: a single-center experience in 94 patients. Diagn Interv Radiol 2020;26:223-9. [PMID: 32209506 DOI: 10.5152/dir.2019.19049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
57 Hayashi H, Shimizu A, Motoyama H, Kubota K, Notake T, Sugenoya S, Hosoda K, Yasukawa K, Kobayashi R, Soejima Y. Usefulness and limitation of indocyanine green fluorescence for detection of peritoneal recurrence after hepatectomy for hepatocellular carcinoma: a case report. BMC Surg 2021;21:107. [PMID: 33653302 DOI: 10.1186/s12893-021-01111-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
58 Li Z, Yuan L, Zhang C, Sun J, Wang Z, Wang Y, Hao X, Gao F, Jiang X. A Novel Prognostic Scoring System of Intrahepatic Cholangiocarcinoma With Machine Learning Basing on Real-World Data. Front Oncol 2020;10:576901. [PMID: 33552957 DOI: 10.3389/fonc.2020.576901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
59 Yang G, Li X, Liu J, Huang S, Weng Y, Zhu J, Lin D, Jiang O. Hsa_circ_0008537 facilitates liver carcinogenesis by upregulating MCL1 and Snail1 expression via miR‑153‑3p. Oncol Rep 2021;45:1072-82. [PMID: 33469676 DOI: 10.3892/or.2021.7941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Oku M, Tokushige K, Maenohara S, Ido A. Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites. J Gastroenterol 2021;56:54-66. [PMID: 32959093 DOI: 10.1007/s00535-020-01727-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
61 Waraasawapati S, Deenonpoe R, Sa-ngiamwibool P, Chamgramol Y, Pairojkul C. Fluke-Associated Cholangiocarcinoma: A Regional Epidemic. Diagnosis and Management of Cholangiocarcinoma 2021. [DOI: 10.1007/978-3-030-70936-5_11] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Tomonari T, Sato Y, Tanaka H, Tanaka T, Taniguchi T, Sogabe M, Okamoto K, Miyamoto H, Muguruma N, Takayama T. Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma. JGH Open 2020;4:1135-9. [PMID: 33319048 DOI: 10.1002/jgh3.12408] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
63 Beppu T, Yamamura K, Okabe H, Imai K, Hayashi H. Oncological benefits of portal vein embolization for patients with hepatocellular carcinoma. Ann Gastroenterol Surg 2021;5:287-95. [PMID: 34095718 DOI: 10.1002/ags3.12414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
64 Yokota T, Nojima H, Kuboki S, Yoshitomi H, Furukawa K, Takayashiki T, Takano S, Ohtsuka M. Sphingosine-1-phosphate Receptor-1 Promotes Vascular Invasion and EMT in Hepatocellular Carcinoma. J Surg Res 2021;259:200-10. [PMID: 33307511 DOI: 10.1016/j.jss.2020.11.044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
65 Kariyama K, Nouso K, Hiraoka A, Wakuta A, Oonishi A, Kuzuya T, Toyoda H, Tada T, Tsuji K, Itobayashi E, Ishikawa T, Takaguchi K, Tsutsui A, Shimada N, Kudo M, Kumada T. EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. Liver Cancer 2020;9:734-43. [PMID: 33442542 DOI: 10.1159/000508971] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
66 Feng JK, Chen ZH, Wu YX, Wang K, Sun JX, Chai ZT, Guo WX, Shi J, Cheng SQ. Comparison of different surgical interventions for hepatocellular carcinoma with bile duct tumor thrombus: a systematic review and meta-analysis. Ann Transl Med 2020;8:1567. [PMID: 33437766 DOI: 10.21037/atm-20-3935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Yang X, Zhu Y, Zhao X, Li JH, Xu D, Jia HL, Zhang JB. The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection. Cancer Manag Res 2020;12:12077-86. [PMID: 33262656 DOI: 10.2147/CMAR.S278777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
68 Gavriilidis P, Hammond JS, Hidalgo E. A systematic review of the impact of portal vein pressure changes on clinical outcomes following hepatic resection. HPB (Oxford) 2020;22:1521-9. [PMID: 32792308 DOI: 10.1016/j.hpb.2020.07.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Ji Y, Zhu J, Zhu L, Zhu Y, Zhao H. High-Intensity Focused Ultrasound Ablation for Unresectable Primary and Metastatic Liver Cancer: Real-World Research in a Chinese Tertiary Center With 275 Cases. Front Oncol 2020;10:519164. [PMID: 33194582 DOI: 10.3389/fonc.2020.519164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
70 Sun M, Shang P, Bai J, Li S, Li M. High-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long-term efficacy and prognosis of primary liver cancer. J Clin Lab Anal 2021;35:e23633. [PMID: 33099812 DOI: 10.1002/jcla.23633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
71 Hiraoka A, Kumada T, Tada T, Ogawa C, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Toyoda H, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Michitaka K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular-carcinoma experts from 48 clinics in Japan). Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2021;9:133-8. [PMID: 34026220 DOI: 10.1093/gastro/goaa042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
72 Chon YE, Lee HA, Yoon JS, Park JY, Kim BH, Lee IJ, Hong SK, Lee DH, Kong H, Kim E, Won Y, Lee J. Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry. J Liver Cancer 2020;20:135-47. [DOI: 10.17998/jlc.20.2.135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
73 Wakizaka K, Kamiyama T, Wakayama K, Orimo T, Shimada S, Nagatsu A, Kamachi H, Yokoo H, Fukai M, Kobayashi N, Mitsuhashi T, Taketomi A. Role of Wnt5a in suppressing invasiveness of hepatocellular carcinoma via epithelial-mesenchymal transition. Oncol Lett 2020;20:268. [PMID: 32989402 DOI: 10.3892/ol.2020.12131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
74 Kamitani N, Nomi T, Hokuto D, Yoshikawa T, Matsuo Y, Sho M. Primary undifferentiated carcinoma with osteoclast-like giant cells in liver and rapidly developing multiple metastases after curative hepatectomy: a case report. Int Cancer Conf J 2020;9:244-8. [PMID: 32904085 DOI: 10.1007/s13691-020-00436-0] [Reference Citation Analysis]
75 Kumada T, Toyoda H, Tada T, Yasuda S, Tanaka J. Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. Liver Cancer 2020;9:518-28. [PMID: 33083278 DOI: 10.1159/000507933] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
76 Tokuda K, Morine Y, Saito Y, Yamada S, Miyazaki K, Yamashita S, Okikawa S, Ikemoto T, Imura S, Shimada M. Effectiveness of repeat surgery for recurrence after primary hepatectomy in patients with intrahepatic cholangiocarcinoma. Int J Clin Oncol 2020;25:2083-9. [PMID: 32869120 DOI: 10.1007/s10147-020-01775-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
77 Yoon JH, Goo YJ, Lim CJ, Choi SK, Cho SB, Shin SS, Jun CH. Features of extrahepatic metastasis after radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol 2020; 26(32): 4833-4845 [PMID: 32921960 DOI: 10.3748/wjg.v26.i32.4833] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
78 Gu W, Tong Z. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis. J Int Med Res 2020;48:300060520946872. [PMID: 32815430 DOI: 10.1177/0300060520946872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
79 Nakajima M, Kobayashi S, Wada H, Tomokuni A, Takahashi H, Noda T, Matsui H, Matsukuma S, Kanekiyo S, Shindo Y, Tokumitsu Y, Nakagami Y, Suzuki N, Takeda S, Tanabe M, Ito K, Hoshii Y, Eguchi H, Nagano H. Viral elimination is essential for improving surgical outcomes of hepatitis C virus-related hepatocellular carcinoma: Multicenter retrospective analysis. Ann Gastroenterol Surg 2020;4:710-20. [PMID: 33319162 DOI: 10.1002/ags3.12377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
80 Nomura A, Ishigami M, Honda T, Kuzuya T, Ishizu Y, Ito T, Kamei H, Onishi Y, Ogura Y, Fujishiro M. Limitation of non-transplant treatment and proper timing for liver transplantation in patients with hepatocellular carcinoma considering long-term survival. Medicine (Baltimore) 2020;99:e21161. [PMID: 32664152 DOI: 10.1097/MD.0000000000021161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
81 Tomonari T, Sato Y, Tanaka H, Tanaka T, Fujino Y, Mitsui Y, Hirao A, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Kagiwada H, Kitazawa M, Fukui K, Horimoto K, Takayama T. Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array. Oncotarget 2020;11:2531-42. [PMID: 32655838 DOI: 10.18632/oncotarget.27640] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
82 Yamamoto M, Kobayashi T, Mashima H, Miki D, Kuroda S, Hamaoka M, Aikata H, Chayama K, Ohdan H. PD1 gene polymorphism is associated with a poor prognosis in hepatocellular carcinoma following liver resection, cohort study. Int J Surg 2020;80:84-90. [PMID: 32615319 DOI: 10.1016/j.ijsu.2020.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
83 Yamamoto M, Kobayashi T, Kuroda S, Hamaoka M, Honmyo N, Yamaguchi M, Takei D, Ohdan H. Impact of postoperative bile leakage on long‐term outcome in patients following liver resection for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2020;27:931-41. [DOI: 10.1002/jhbp.750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
84 Zhang T, Pandey G, Xu L, Chen W, Gu L, Wu Y, Chen X. The Value of TTPVI in Prediction of Microvascular Invasion in Hepatocellular Carcinoma. Cancer Manag Res 2020;12:4097-105. [PMID: 32581583 DOI: 10.2147/CMAR.S245475] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
85 Lee JY, Minami Y, Choi BI, Lee WJ, Chou YH, Jeong WK, Park MS, Kudo N, Lee MW, Kamata K, Iijima H, Kim SY, Numata K, Sugimoto K, Maruyama H, Sumino Y, Ogawa C, Kitano M, Joo I, Arita J, Liang JD, Lin HM, Nolsoe C, Gilja OH, Kudo M. The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid. J Med Ultrasound 2020;28:59-82. [PMID: 32874864 DOI: 10.4103/JMU.JMU_124_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
86 Shinkawa H, Tanaka S, Takemura S, Ishihara T, Yamamoto K, Kubo S. Tumor Size Drives the Prognosis After Hepatic Resection of Solitary Hepatocellular Carcinoma Without Vascular Invasion. J Gastrointest Surg 2020;24:1040-8. [PMID: 31197685 DOI: 10.1007/s11605-019-04273-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
87 Hiraoka A, Nagamatsu K, Izumoto H, Yoshino T, Adachi T, Tsuruta M, Aibiki T, Okudaira T, Yamago H, Suga Y, Iwasaki R, Mori K, Miyata H, Tsubouchi E, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K. SARC-F combined with a simple tool for assessment of muscle abnormalities in outpatients with chronic liver disease. Hepatol Res 2020;50:502-11. [PMID: 31830344 DOI: 10.1111/hepr.13469] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
88 Artemkin E, Kryukov E, Ovsyannikova M, Sokolov A, Sokolov D, Tychinskaya K, Kelzin A. First experience of intraductal photodynamic Klatskin tumor therapy by using SpyGlass ™ DS technology in Russia. Hirurg (Surgeon) 2020. [DOI: 10.33920/med-15-2002-06] [Reference Citation Analysis]
89 Shindoh J, Kobayashi Y, Kawamura Y, Akuta N, Kobayashi M, Suzuki Y, Ikeda K, Hashimoto M. Microvascular Invasion and a Size Cutoff Value of 2 cm Predict Long-Term Oncological Outcome in Multiple Hepatocellular Carcinoma: Reappraisal of the American Joint Committee on Cancer Staging System and Validation Using the Surveillance, Epidemiology, and End-Results Database. Liver Cancer 2020;9:156-66. [PMID: 32399430 DOI: 10.1159/000504193] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
90 Yoon JS, Lee HA, Park JY, Kim BH, Lee IJ, Chon YE, Hong SK, Lee DH, Kong H, Won Y, Kim E, Lee J. Hepatocellular Carcinoma in Korea Between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry. J Liver Cancer 2020;20:41-52. [DOI: 10.17998/jlc.20.1.41] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
91 Chen H, Jia W. Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. Genes Dis 2020;7:320-7. [PMID: 32884986 DOI: 10.1016/j.gendis.2020.02.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
92 Watanabe Y, Matsuyama Y, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Kudo M. Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: A nationwide survey of the Liver Cancer Study Group of Japan. Surgery 2020;167:793-802. [PMID: 32044110 DOI: 10.1016/j.surg.2019.12.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
93 Matsukuma S, Eguchi H, Wada H, Noda T, Shindo Y, Tokumitsu Y, Matsui H, Takahashi H, Kobayashi S, Nagano H. Liver resection with thrombectomy for patients with hepatocellular carcinoma and tumour thrombus in the inferior vena cava or right atrium. BJS Open 2020;4:241-51. [PMID: 32012492 DOI: 10.1002/bjs5.50258] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
94 Tani J, Morishita A, Sakamoto T, Takuma K, Nakahara M, Fujita K, Oura K, Tadokoro T, Mimura S, Nomura T, Yoneyama H, Kobara H, Himoto T, Tsutsui A, Senoh T, Nagano T, Ogawa C, Moriya A, Deguchi A, Takaguchi K, Masaki T. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. Oncol Lett. 2020;19:2205-2212. [PMID: 32194718 DOI: 10.3892/ol.2020.11341] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
95 Morio K, Kawaoka T, Aikata H, Namba M, Uchikawa S, Kodama K, Ohya K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Nakamura Y, Akagi M, Awai K, Kobayashi T, Ohdan H, Chayama K. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection. Eur J Radiol. 2020;124:108828. [PMID: 31955034 DOI: 10.1016/j.ejrad.2020.108828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
96 Tomonari T, Sato Y, Tanaka H, Tanaka T, Fujino Y, Mitsui Y, Hirao A, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Kagiwada H, Kitazawa M, Fukui K, Horimoto K, Takayama T. Therapeutic Efficacy and Safety of Lenvatinib for Unresectable Hepatocellular Carcinoma Beyond Progression with Sorafenib.. [DOI: 10.1101/2020.01.03.893800] [Reference Citation Analysis]
97 Kariyama K, Nouso K, Wakuta A, Oonishi A, Toyoda H, Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Takaguchi K, Tsutsui A, Shimada N, Kumada T. Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies. Liver Cancer 2020;9:41-9. [PMID: 32071908 DOI: 10.1159/000502479] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
98 Cortese S, Morales J, Martín L, Kayser S, Colón A, Ramón E, Tellado JM. Resección hepática con trombectomía en el tratamiento del carcinoma hepatocelular con invasión vascular macroscópica. Cirugía Española 2020;98:9-17. [DOI: 10.1016/j.ciresp.2019.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
99 Bashkatov AN, Zakharov VP, Bucharskaya AB, Borisova EG, Khristoforova YA, Genina EA, Tuchin VV. Malignant Tissue Optical Properties. Multimodal Optical Diagnostics of Cancer 2020. [DOI: 10.1007/978-3-030-44594-2_1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Cortese S, Morales J, Martín L, Kayser S, Colón A, Ramón E, Tellado JM. Hepatic Resection With Thrombectomy in the Treatment of Hepatocellular Carcinoma Associated With Macrovascular Invasion. Cirugía Española (English Edition) 2020;98:9-17. [DOI: 10.1016/j.cireng.2019.12.011] [Reference Citation Analysis]
101 Hiraoka A, Kumada T, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Yokohama K, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M. Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer 2020;9:73-83. [PMID: 32071911 DOI: 10.1159/000503031] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
102 Matsunaga K, Okuse C, Nakamura S, Suetani K, Ishigooka S, Itoh F, Suzuki M. Current Status of Hepatocellular Carcinoma Occurrence after Achieving a Sustained Virologic Response with Direct-Acting Antiviral Drug Treatment for Type C Chronic Liver Disease: A Study at Kawasaki Municipal Tama Hospital. J St Marianna Univ 2020;11:143-152. [DOI: 10.17264/stmarieng.11.143] [Reference Citation Analysis]
103 Qi F, Zhou A, Yan L, Yuan X, Wang D, Chang R, Zhang Y, Shi F, Han X, Hou J, Wei L, Zhang X. The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma. J Clin Lab Anal 2020;34:e23158. [PMID: 31821607 DOI: 10.1002/jcla.23158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
104 Zhang XP, Chai ZT, Gao YZ, Chen ZH, Wang K, Shi J, Guo WX, Zhou TF, Ding J, Cong WM, Xie D, Lau WY, Cheng SQ. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. HPB (Oxford) 2019;21:1687-96. [PMID: 31153833 DOI: 10.1016/j.hpb.2019.04.014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
105 Adhoute X, Pénaranda G, Raoul JL, Pietri O, Bronowicki JP, Castellani P, Perrier H, Monnet O, Bayle O, Oules V, Pol B, Beaurain P, Muller C, Cassagneau P, Bourlière M. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort. Eur J Gastroenterol Hepatol 2019;31:1414-23. [PMID: 31045613 DOI: 10.1097/MEG.0000000000001420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
106 Hanai T, Shiraki M, Watanabe S, Imai K, Suetsugu A, Takai K, Moriwaki H, Shimizu M. Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: A propensity score-matching analysis. J Gastroenterol Hepatol 2019;34:1809-16. [PMID: 30779213 DOI: 10.1111/jgh.14635] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
107 Hiraoka A, Kumada T, Michitaka K, Kudo M. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer 2019;8:312-25. [PMID: 31768342 DOI: 10.1159/000494844] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 13.5] [Reference Citation Analysis]
108 Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Eguchi S, Yamashita T, Kudo M. Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. Liver Cancer 2019;8:403-11. [PMID: 31768348 DOI: 10.1159/000495944] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
109 Yang XW, Fu XH, Zhang YJ. Clinical and pathological characteristics of cholangiolocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2019; 27(18): 1114-1117 [DOI: 10.11569/wcjd.v27.i18.1114] [Reference Citation Analysis]
110 Ishikawa T, Sasaki R, Nishimura T, Aibe Y, Saeki I, Iwamoto T, Hidaka I, Takami T, Sakaida I. A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification. PLoS One 2019;14:e0223153. [PMID: 31557230 DOI: 10.1371/journal.pone.0223153] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
111 Yamamoto M, Kobayashi T, Kuroda S, Hamaoka M, Okimoto S, Honmyo N, Yamaguchi M, Ohdan H. Verification of inflammation-based prognostic marker as a prognostic indicator in hepatocellular carcinoma. Ann Gastroenterol Surg 2019;3:667-75. [PMID: 31788655 DOI: 10.1002/ags3.12286] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
112 Kim N, You MW. Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. Jpn J Radiol 2019;37:781-92. [PMID: 31522384 DOI: 10.1007/s11604-019-00868-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
113 Lu W, Tang H, Yang Z, Jiang K, Chen Y, Lu S. Clinical predictors of small solitary hepatitis B virus-related hepatocellular carcinoma microinvasion. ANZ J Surg 2019;89:E438-42. [PMID: 31508888 DOI: 10.1111/ans.15403] [Reference Citation Analysis]
114 Lu J, Zhang X, Zhong B, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng S, Teng G. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019;4:721-30. [DOI: 10.1016/s2468-1253(19)30178-5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 12.5] [Reference Citation Analysis]
115 Shao SY, Hu QD, Wang M, Zhao XY, Wu WT, Huang JM, Liang TB. Impact of national Human Development Index on liver cancer outcomes: Transition from 2008 to 2018. World J Gastroenterol 2019; 25(32): 4749-4763 [PMID: 31528099 DOI: 10.3748/wjg.v25.i32.4749] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
116 Park HK, Lee SS, Im CB, Im C, Cha RR, Kim WS, Cho HC, Lee JM, Kim HJ, Kim TH, Jung WT, Lee OJ. Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma. BMC Cancer 2019;19:822. [PMID: 31429755 DOI: 10.1186/s12885-019-6040-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
117 Heo CK, Hwang HM, Lee HJ, Kwak SS, Yoo JS, Yu DY, Lim KJ, Lee S, Cho EW. Serum anti-EIF3A autoantibody as a potential diagnostic marker for hepatocellular carcinoma. Sci Rep 2019;9:11059. [PMID: 31363116 DOI: 10.1038/s41598-019-47365-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
118 Iwasa M, Ishihara T, Kato M, Isoai A, Kobayashi R, Torii N, Soneda N, Takei Y. Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan. Intern Med 2019;58:3069-75. [PMID: 31292400 DOI: 10.2169/internalmedicine.3091-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
119 Ochiai T, Inoue H, Watanabe N, Ito H, Toma A, Morimura R, Ikoma H, Otsuji E. Outcome of a second hepatectomy in octogenarians with hepatocellular carcinoma recurrence: single centre's experience. ANZ J Surg 2019;89:1270-4. [PMID: 31280497 DOI: 10.1111/ans.15330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
120 Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Yada T, Inada Y, Sakamoto H, Higashi H, Kubozono O, Maenohara S, Ido A. Effect of tolvaptan on the prognosis of patients with hepatic ascites. Hepatol Res 2019;49:765-77. [PMID: 30916842 DOI: 10.1111/hepr.13337] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
121 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy. PLoS One 2019;14:e0218136. [PMID: 31194789 DOI: 10.1371/journal.pone.0218136] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
122 Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. Cancer Med 2019;8:3719-28. [PMID: 31127698 DOI: 10.1002/cam4.2241] [Cited by in Crossref: 95] [Cited by in F6Publishing: 105] [Article Influence: 23.8] [Reference Citation Analysis]
123 Patella F, Pesapane F, Fumarola E, Zannoni S, Brambillasca P, Emili I, Costa G, Anderson V, Levy EB, Carrafiello G, Wood BJ. Assessment of the response of hepatocellular carcinoma to interventional radiology treatments. Future Oncol 2019;15:1791-804. [PMID: 31044615 DOI: 10.2217/fon-2018-0747] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
124 Jang TY, Huang CI, Yeh ML, Lin ZY, Chen SC, Chuang WL. The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis. Medicine (Baltimore) 2019;98:e15066. [PMID: 30921239 DOI: 10.1097/MD.0000000000015066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
125 Ronot M, Purcell Y, Vilgrain V. Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis. Dig Dis Sci 2019;64:934-50. [PMID: 30825108 DOI: 10.1007/s10620-019-05547-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
126 Shinke G, Yamada D, Eguchi H, Iwagami Y, Akita H, Asaoka T, Noda T, Gotoh K, Kobayashi S, Takeda Y, Tanemura M, Doki Y, Mori M. The postoperative peak number of leukocytes after hepatectomy is a significant prognostic factor for cholangiocarcinoma. Mol Clin Oncol 2019;10:531-40. [PMID: 31007913 DOI: 10.3892/mco.2019.1827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
127 Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K, Kudo M. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer 2019;8:121-9. [PMID: 31019902 DOI: 10.1159/000488778] [Cited by in Crossref: 102] [Cited by in F6Publishing: 104] [Article Influence: 25.5] [Reference Citation Analysis]
128 Huang K, Liao X, Han C, Wang X, Yu T, Yang C, Liu X, Yu L, Chen Z, Qin W, Zhu G, Su H, Liu Z, Zeng X, Zhou X, Lu S, Huang J, Liang Y, Liu Z, Deng J, Ye X, Peng T. Genetic variants and Expression of Cytochrome p450 Oxidoreductase Predict Postoperative Survival in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. J Cancer 2019;10:1453-65. [PMID: 31031855 DOI: 10.7150/jca.28919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
129 Hiraoka A, Izumoto H, Ueki H, Yoshino T, Aibiki T, Okudaira T, Yamago H, Suga Y, Iwasaki R, Tomida H, Mori K, Miyata H, Tsubouchi E, Kishida M, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K. Easy surveillance of muscle volume decline in chronic liver disease patients using finger-circle (yubi-wakka) test. J Cachexia Sarcopenia Muscle 2019;10:347-54. [PMID: 30793533 DOI: 10.1002/jcsm.12392] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
130 Kariyama K, Nouso K, Toyoda H, Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Wakuta A, Oonishi A, Kumada T, Kudo M, Group OBOTRPEFHRS, Group H. Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E203. [PMID: 30744175 DOI: 10.3390/cancers11020203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
131 Kim YY, Park MS, Aljoqiman KS, Choi JY, Kim MJ. Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers. Clin Mol Hepatol 2019;25:223-33. [PMID: 30661336 DOI: 10.3350/cmh.2018.0107] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
132 Nagata K, Einama T, Kimura A, Murayama M, Takeo H, Nishikawa M, Hoshikawa M, Noro T, Ogata S, Aosasa S, Kajiwara Y, Shinto E, Yaguchi Y, Hiraki S, Tsujimoto H, Hase K, Ueno H, Yamamoto J. A case of intrahepatic cholangiocarcinoma that was difficult to diagnose prior to surgery: A case report. Oncol Lett 2019;17:823-30. [PMID: 30655835 DOI: 10.3892/ol.2018.9666] [Reference Citation Analysis]
133 Moran A, Ramos LF, Picado O, Pendola F, Sleeman D, Dudeja V, Merchant N, Yakoub D. Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and meta-analysis. J Surg Oncol 2019;119:455-63. [PMID: 30575028 DOI: 10.1002/jso.25338] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
134 Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Shibata H, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med 2019;8:137-46. [PMID: 30575325 DOI: 10.1002/cam4.1909] [Cited by in Crossref: 93] [Cited by in F6Publishing: 94] [Article Influence: 18.6] [Reference Citation Analysis]
135 Zhou C, Zu QQ, Wang B, Zhou CG, Shi HB, Liu S. Efficacy and prognostic factors of transarterial embolization as initial treatment for spontaneously ruptured hepatocellular carcinoma: a single-center retrospective analysis in 57 patients. Jpn J Radiol 2019;37:255-63. [PMID: 30511145 DOI: 10.1007/s11604-018-0799-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
136 Kawaoka T, Aikata H, Kobayashi T, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Inagaki Y, Honda F, Hatooka M, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Baba Y, Awai K, Chayama K. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. Hepatol Res 2018;48:1118-30. [PMID: 30030881 DOI: 10.1111/hepr.13232] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
137 Hu Z, Huang P, Yan Y, Zhou Z, Wang J, Wu G. Hepatitis B virus X protein related lncRNA WEE2-AS1 promotes hepatocellular carcinoma proliferation and invasion. Biochem Biophys Res Commun 2019;508:79-86. [PMID: 30471857 DOI: 10.1016/j.bbrc.2018.11.091] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
138 Yamane T, Imai K, Umezaki N, Yamao T, Kaida T, Nakagawa S, Yamashita YI, Chikamoto A, Ishiko T, Baba H. Perforation of the esophagus due to thermal injury after laparoscopic radiofrequency ablation for hepatocellular carcinoma: a case for caution. Surg Case Rep. 2018;4:127. [PMID: 30315431 DOI: 10.1186/s40792-018-0534-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
139 Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiotherapy and Oncology 2018;129:112-22. [DOI: 10.1016/j.radonc.2017.11.013] [Cited by in Crossref: 54] [Cited by in F6Publishing: 62] [Article Influence: 10.8] [Reference Citation Analysis]
140 Saeki I, Yamasaki T, Maeda M, Kawano R, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma. Liver Cancer 2018;7:359-71. [PMID: 30488024 DOI: 10.1159/000487858] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
141 Kudo M. Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma. Liver Cancer 2018;7:215-24. [PMID: 30319981 DOI: 10.1159/000492533] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
142 Guzman-Lepe J, Cervantes-Alvarez E, Collin de l'Hortet A, Wang Y, Mars WM, Oda Y, Bekki Y, Shimokawa M, Wang H, Yoshizumi T, Maehara Y, Bell A, Fox IJ, Takeishi K, Soto-Gutierrez A. Liver-enriched transcription factor expression relates to chronic hepatic failure in humans. Hepatol Commun 2018;2:582-94. [PMID: 29761173 DOI: 10.1002/hep4.1172] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
143 Minami K, Hiwatashi K, Ueno S, Sakoda M, Iino S, Okumura H, Hashiguchi M, Kawasaki Y, Kurahara H, Mataki Y, Maemura K, Shinchi H, Natsugoe S. Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma. Exp Ther Med 2018;15:4465-76. [PMID: 29731831 DOI: 10.3892/etm.2018.5959] [Cited by in Crossref: 17] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
144 Yamao T, Imai K, Yamashita YI, Kaida T, Nakagawa S, Mima K, Hashimoto D, Chikamoto A, Ishiko T, Baba H. Surgical treatment strategy for hepatocellular carcinoma in patients with impaired liver function: hepatic resection or radiofrequency ablation? HPB (Oxford) 2018;20:244-50. [PMID: 28988913 DOI: 10.1016/j.hpb.2017.08.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
145 Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T; Miriplatin TACE Study Group. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. J Gastroenterol 2018;53:281-90. [PMID: 28766016 DOI: 10.1007/s00535-017-1374-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
146 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2017;6:387-396. [PMID: 29312973 DOI: 10.21037/hbsn.2017.11.01] [Cited by in Crossref: 39] [Cited by in F6Publishing: 50] [Article Influence: 6.5] [Reference Citation Analysis]
147 Kimura K, Nakamura T, Ono T, Azami Y, Suzuki M, Wada H, Takayama K, Endo H, Takeyama T, Hirose K, Takai Y, Kikuchi Y. Clinical results of proton beam therapy for hepatocellular carcinoma over 5 cm. Hepatol Res 2017;47:1368-74. [PMID: 28198132 DOI: 10.1111/hepr.12874] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
148 Ye JZ, Chen JZ, Li ZH, Bai T, Chen J, Zhu SL, Li LQ, Wu FX. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion. World J Gastroenterol 2017; 23(41): 7415-7424 [PMID: 29151695 DOI: 10.3748/wjg.v23.i41.7415] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 60] [Article Influence: 8.8] [Reference Citation Analysis]
149 Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer 2017;6:325-36. [PMID: 29234636 DOI: 10.1159/000479984] [Cited by in Crossref: 135] [Cited by in F6Publishing: 136] [Article Influence: 22.5] [Reference Citation Analysis]
150 Sugihara T, Koda M, Okamoto T, Miyoshi K, Matono T, Isomoto H. Two patterns of contrast-enhanced ultrasonography with Sonazoid® in spontaneous rupture of hepatocellular carcinoma: a report of four cases. J Med Ultrason (2001) 2018;45:319-23. [PMID: 28815352 DOI: 10.1007/s10396-017-0812-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
151 Shinkawa H, Hasegawa K, Arita J, Akamatsu N, Kaneko J, Sakamoto Y, Kokudo N. Impact of Sustained Virological Response to Interferon Therapy on Recurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma. Ann Surg Oncol 2017;24:3196-202. [DOI: 10.1245/s10434-017-6008-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
152 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 986] [Cited by in F6Publishing: 915] [Article Influence: 164.3] [Reference Citation Analysis]
153 Yuri Y, Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Hasegawa K, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Takata R, Iijima H, Nishiguchi S. Implication of Psoas Muscle Index on Survival for Hepatocellular Carcinoma Undergoing Radiofrequency Ablation Therapy. J Cancer 2017;8:1507-16. [PMID: 28775769 DOI: 10.7150/jca.19175] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
154 Qiu B, Li K, Dong X, Liu FQ. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol. 2017;40:1372-1382. [PMID: 28488102 DOI: 10.1007/s00270-017-1655-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
155 Waked I, Berhane S, Toyoda H, Chan SL, Stern N, Palmer D, Tada T, Yeo W, Mo F, Bettinger D, Kirstein MM, Iñarrairaegui M, Gomaa A, Vogel A, Meyer T, Sangro B, Lai P, Kumada T, Johnson PJ. Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br J Cancer 2017;116:448-54. [PMID: 28125820 DOI: 10.1038/bjc.2016.423] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 8.3] [Reference Citation Analysis]
156 Zhao H, Hua Y, Dai T, He J, Tang M, Fu X, Mao L, Jin H, Qiu Y. Development and validation of a novel predictive scoring model for microvascular invasion in patients with hepatocellular carcinoma. Eur J Radiol 2017;88:32-40. [PMID: 28189206 DOI: 10.1016/j.ejrad.2016.12.030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
157 Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8967-8977 [PMID: 27833388 DOI: 10.3748/wjg.v22.i40.8967] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
158 Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol 2016; 22(32): 7289-7300 [PMID: 27621575 DOI: 10.3748/wjg.v22.i32.7289] [Cited by in CrossRef: 99] [Cited by in F6Publishing: 105] [Article Influence: 14.1] [Reference Citation Analysis]
159 Arai K, Fukumoto T, Kido M, Tanaka M, Kuramitsu K, Kinoshita H, Komatsu S, Tsugawa D, Terai S, Matsumoto T, Goto T, Asari S, Toyama H, Ajiki T, Ku Y. Preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after reductive surgery plus percutaneous isolated hepatic perfusion for hepatocellular carcinoma: a retrospective analysis. Surg Today. 2017;47:385-392. [PMID: 27465474 DOI: 10.1007/s00595-016-1384-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
160 Arai K, Fukumoto T, Tanaka M, Kuramitsu K, Kido M, Kinoshita H, Matsumoto T, Toyama H, Asari S, Goto T, Ajiki T, Ku Y. Pathological complete response after percutaneous isolated hepatic perfusion in hepatocellular carcinoma with portal vein tumor thrombosis: a case report. Surg Case Rep 2016;2:50. [PMID: 27230652 DOI: 10.1186/s40792-016-0178-x] [Reference Citation Analysis]
161 Katsuta E, Kudo A, Akashi T, Mitsunori Y, Matsumura S, Aihara A, Ban D, Ochiai T, Tanaka S, Eishi Y, Tanabe M. Macroscopic morphology for estimation of malignant potential in pancreatic neuroendocrine neoplasm. J Cancer Res Clin Oncol 2016;142:1299-306. [PMID: 26885661 DOI: 10.1007/s00432-016-2128-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
162 Thurm T, Shibolet O. Clinical Features and Clinician’s Diagnostic Approach to Hepatocellular Carcinoma. Hepatocellular Carcinoma 2016. [DOI: 10.1007/978-3-319-34214-6_27] [Reference Citation Analysis]
163 Carr BI, Nagalla S, Geva R. Medical Therapy of HCC. Hepatocellular Carcinoma 2016. [DOI: 10.1007/978-3-319-34214-6_33] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
164 Okumura T, Ide T, Miyoshi A, Kitahara K, Noshiro H. Resection of the Intraductal Growth Type of Intrahepatic Cholangiocarcinoma Following a Long-Term Observation: a Rare Case Report. J Gastrointest Cancer 2016;47:458-61. [PMID: 26459232 DOI: 10.1007/s12029-015-9768-2] [Reference Citation Analysis]
165 Shinoda K, Kuboki S, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Furukawa K, Miyazaki M. Pin1 facilitates NF-κB activation and promotes tumour progression in human hepatocellular carcinoma. Br J Cancer. 2015;113:1323-1331. [PMID: 26461058 DOI: 10.1038/bjc.2015.272] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
166 Arizumi T, Ueshima K, Takeda H, Osaki Y, Takita M, Inoue T, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. J Gastroenterol 2014;49:1578-87. [PMID: 24499826 DOI: 10.1007/s00535-014-0936-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
167 Imai Y, Chikayama T, Nakazawa M, Watanabe K, Ando S, Mizuno Y, Yoshino K, Sugawara K, Hamaoka K, Fujimori K, Inao M, Nakayama N, Oka M, Nagoshi S, Mochida S. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Gastroenterol 2012;47:179-86. [PMID: 21976133 DOI: 10.1007/s00535-011-0475-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
168 Une Y, Misawa K, Shimamura T, Ogasawara K, Masuko Y, Sato N, Nakajima Y, Uchino J. Treatment of lymph node recurrence in patients with hepatocellular carcinoma. Surg Today 1994;24:606-9. [PMID: 7949768 DOI: 10.1007/BF01833724] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 0.9] [Reference Citation Analysis]